Close Menu

NEW YORK (GenomeWeb) – BATM Advanced Communications, an Israeli firm focused on real-time technologies for networking and medical laboratories, has agreed to invest up to $30 million in Ador Diagnostics, BATM's joint venture with Gamida for Life.

The funds will go toward commercialization of Ador's NATlab reader, a point-of-care molecular diagnostics platform that uses microarray cartridges to enable sample-to-answer identification of specific infectious diseases.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.